.2

Arcadia Biosciences, Inc.
Consolidated Balance Sheets
(Unaudited)
(In thousands, except share data)
|
|
|
|
|
|
|
||
|
|
June 30, 2025 |
|
|
December 31, 2024 |
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
1,376 |
|
|
$ |
4,242 |
|
Short-term investments |
|
|
3,067 |
|
|
|
— |
|
Accounts receivable and other receivables, net of allowance for credit losses of |
|
|
1,264 |
|
|
|
1,175 |
|
Inventories |
|
|
1,489 |
|
|
|
904 |
|
Note receivable — current, net of allowance for credit losses (Note 7) |
|
|
— |
|
|
|
1,894 |
|
Prepaid expenses and other current assets |
|
|
383 |
|
|
|
931 |
|
Current assets of discontinued operations — GoodWheat |
|
|
— |
|
|
|
96 |
|
Total current assets |
|
|
7,579 |
|
|
|
9,242 |
|
Property and equipment, net |
|
|
12 |
|
|
|
41 |
|
Right of use asset |
|
|
10 |
|
|
|
137 |
|
Intangible assets, net |
|
|
39 |
|
|
|
39 |
|
Note receivable — noncurrent, net of allowance for credit losses (Note 7) |
|
|
— |
|
|
|
3,966 |
|
Other noncurrent assets |
|
|
148 |
|
|
|
92 |
|
Total assets |
|
$ |
7,788 |
|
|
$ |
13,517 |
|
Liabilities and stockholders’ equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable and accrued expenses |
|
$ |
1,558 |
|
|
$ |
2,108 |
|
Amounts due to related parties |
|
|
— |
|
|
|
30 |
|
Operating lease liability — current |
|
|
11 |
|
|
|
155 |
|
Other current liabilities |
|
|
270 |
|
|
|
270 |
|
Total current liabilities |
|
|
1,839 |
|
|
|
2,563 |
|
Common stock warrant and option liabilities |
|
|
1,416 |
|
|
|
2,731 |
|
Other noncurrent liabilities |
|
|
— |
|
|
|
2,000 |
|
Total liabilities |
|
|
3,255 |
|
|
|
7,294 |
|
Commitments and contingencies (Note 14) |
|
|
|
|
|
|
||
Stockholders’ equity: |
|
|
|
|
|
|
||
Common stock, $0.001 par value—150,000,000 shares authorized as |
|
|
65 |
|
|
|
65 |
|
Additional paid-in capital |
|
|
285,205 |
|
|
|
285,036 |
|
Accumulated deficit |
|
|
(280,737 |
) |
|
|
(278,878 |
) |
Total stockholders' equity |
|
|
4,533 |
|
|
|
6,223 |
|
Total liabilities and stockholders’ equity |
|
$ |
7,788 |
|
|
$ |
13,517 |
|